Tinea versicolor

International Journal of Dermatology

Volumn 37, Issue 9, 1998, Pages 648-655

  Sunenshine, Peter J ^a   Schwartz, Robert A ^a   Janniger, Camila K ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOTRIMAZOLE; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; SALICYLIC ACID; SELENIUM SULFIDE; SODIUM THIOSULFATE; TERBINAFINE; TINVER; UNCLASSIFIED DRUG;

DIFFERENTIAL DIAGNOSIS; HISTOPATHOLOGY; HUMAN; INFECTION PREVENTION; ORAL DRUG ADMINISTRATION; PITYROSPORUM ORBICULARE; PITYROSPORUM OVALE; RECURRENT DISEASE; REVIEW; TINEA VERSICOLOR; TOPICAL DRUG ADMINISTRATION;

ANTIFUNGAL AGENTS; HUMANS; MALASSEZIA; SKIN; TINEA VERSICOLOR;

EID: 0031784223     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.1998.00441.x     Document Type: Review

References (105)

1. Michalowski R, Rodziewicz H. Pityriasis versicolor in children. Br J Dermatol 1963-75: 397-400.
2. Adamski Z. Studies of a role played by lipophilic yeasts Malassezia furfur (Pityrosporum ovale, Pityrosporum orbiculare) in different dermatoses. Postepy Dermatol (Poznan) 1995; 12: 349-454.
3. Baillon H. Traite de Botanique Medicale Cryptogamique. Paris: Octave Doin, 1889: 234.
4. Robin C. Historie Naturelle des Vegeaux Parasites. London: Balliere, 1853: 438.
5. Rivolta S. Dei Parasstti Vegetali come Introduzione allo Studio delle Malattie Parassitarei. E delle Alterazioni dell'alimento degli Aimali Domestici. Torino, Italy: Speir, 1873: 469-479.
6. Gordon MA. The lipophilic mycoflora of the skin. Mycologica 1951; 43: 524-534.
7. Castellani A, Chalmers AJ. Manual of Tropical Medicine, 2nd edn. New York: Wm. Wood & Co., 1913: 836-837.
8. Gordon MA. Lipophilic yeastlike organisms associated with tinea versicolor. J Invest Dermatol 1951; 17: 267-272.
9. Akpata LE, Gugnani HC, Utsalo SJ. Pityriasis versicolor in school children in Cross River State of Nigeria. Mycoses 1990; 33: 549-551.
10. Bergbrant IM, Faergemann J. Variations of Pityrosporum orbiculare in middle-aged and elderly individuals. Acta Derm Venereol (Stockh) 1988; 68: 537-540.
11. Bergbrant I-M, Brobeg A. Pityrosporum ovale culture from the forehead of healthy children. Acta Derm Venereol (Stockh) 1994; 74: 260-261.
12. Terragni L, Lasagni A, Oriani A, Gelmetti C. Pityriasis versicolor in the pediatric age. Pediatr Dermatol 1991; 8: 9-12.
13. Miskeen AK, Kelkar SS, Shroff HJ. Pityriasis versicolor in children. Indian J Dermatol Venereol Leprol 1984; 50: 144-146.
14. Savin R. Diagnosis and treatment of tinea versicolor. J Fam Pract 1996; 43: 127-132.
15. Faergemann J. Tinea versicolor (tinea pityriasis versicolor). In: Demis D, ed. Clinical Dermatology. Philadelphia: Unit 17-2, Lippincott-Raven, 1995: 1-11.
16. Nowicki R, Sadowska E. Mycotic infections in the Gdansk area. Przegl Dermatol 1993; 80: 245-250.
17. Faergemann J. Lipophilic yeasts in skin disease. Semin Dermatol 1985; 4: 173-184.
18. Andrzejewska E, Adamski Z, Mycological diagnostics of lipophylic yeasts Malassezia furfur (pityrosporum spp.). Postepy Dermatol (Poznan) 1993; 10: 223-228.
19. Sloof WC. Genus Pityrosporum. In: Lodder J, ed. The Yeasts, 2nd edn. Amsterdam: North-Holland, 1971: 1167-1186.
20. Faergemann J, Bernander S. Micro-aerophilic and anaerobic growth of Pityrosporum orbiculare. Sabouraudic 1981; 19: 117-121.
21. Faergemann J, Aly R, Maibach HI. Growth and filament production of Pityrosporum orbiculare and P. ovale on human stratum corneum in vitro. Acta Derm Venereol (Stockh) 1983; 63: 388-392.
22. Roberts SOB. Pityrosporum orbiculare: incidence and distribution on clinically normal skin. Br J Dermatol 1969; 81: 164-169.
23. Salkin IF, Gordon MA. Polymorphism of Malassezia furfur. Can J Microbiol 1977; 23: 471-475.
24. Faergemann J, Tjernlund U, Scheynius A, Sverker B. Antigenic similarities and differences in genus Pityrosporum. J Invest Dermatol 1982; 78: 28-31.
25. Sternberg TH, Keddie FM. Immunofluorescence studies in tinea versicolor. Arch Dermatol 1961; 84: 999-1003.
26. Cunningham AC, Leeming JP, Ingham E, Gowland G. Differentiation of three serovars of Malassezia furfur. J Appl Bacterial 1990; 68: 439-446.
27. Ashbee HR, Ingham E, Holland KT, Cunliffe WJ. The carriage of Malassezia furfur serovars A, B, and C in patients with pityriasis versicolor, seborrhoeic dermatitis and controls. Br J Dermatol 1993; 129: 533-540.
28. Ashbee HR, Ingham E, Holland KT, et al. The role of Malassezia furfur serovars A, B, and C in pityriasis versicolor and seborrhoeic dermatitis. Br J Dermatol 1991; 125: 495.
29. Schmidt A. Malassezia furfur: a fungus belonging to the physiological skin flora and its relevance in skin disorders. Cutis 1997; 59: 21-24.
30. Leeming JP, Notman FH, Holland KT. The distribution and ecology of Malassezia furfur and cutaneous bacteria on human skin. J Appl Bacteriol 1989; 67: 47-52.
31. Breathnach AS, Nazzaro Porro M, Martin B. Ultrastructure of skin in pityriasis versicolor. Giornale Italiano di Dermatologia-Minerva Dermatologica 1975; 110: 457-469.
32. Scheynius A, Faergemann J, Forsum U, Sjoberg O. Phenotypic characterization in situ of inflammatory cells in pityriasis (tinea) versicolor. Acta Derm Venereol (Stockh) 1984; 64: 473-479.
33. King RD, Cunico RL, Maibach HI, et al. The effect of occlusion on carbon dioxide emission from human skin. Acta Derm Venereol (Stockh) 1978; 58: 135-138.
34. Faergemann J, Bernander S. Tinea versicolor and Pityrosporum orbiculare. A mycological investigation. Sabouraudia 1979; 17: 171-179.
35. Congly H. Pityriasis versicolor in a 3-month-old boy. Can Med Assoc J 1984; 130: 844-845.
36. Roberts SOB. Pityriasis versicolor: a clinical and mycological investigation. Br J Dermatol 1969; 81: 315-316.
37. Burke RC. Tinea versicolor: susceptibility factors and experimental infections in human beings. J Invest Dermatol 1961; 36: 389-402.
38. Elewski BE, Hazen PG. The superficial mycoses and the dermatophytes. J Am Acad Dermatol 1989; 21: 655-673.
39. Heng MCY, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityrosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol 1990; 23: 82-86.
40. Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol 1986; 114: 695-700.
41. Schechtman RC, Midgley G, Hay RJ. HIV disease and Malassezia yeasts: a quantitative study of patients presenting with seborrhoeic dermatitis. Br J Dermatol 1995; 133: 694-698.
42. Groisser D, Bottone EJ, Lebwohl M. Association of Pityrosporum orbiculare (Malassezia furfur) with seborrheic dermatitis in patients with acquired immunodeficiency syndrome (AIDS). J Am Acad Dermatol 1989; 20: 770-773.
43. Urbanowski S, Gwiezdzinski Z, Nierebinska E. Contemporary views on the etiopathogenesis and treatment of seborrheic dermatitis and dandruff. Przegl Dermatol 1992; 49: 402-408.
44. Crozier WJ, Wise KA. Onychomycosis due to Pityrosporum. Australas J Dermatol 1993; 34: 109-112.
45. Macura AB, Budak A, Pawlik B, et al. Fungal infections of the skin and nails in patients attending the department of mycology at the Jagiellonian University Collegium Medicum Institute of Microbiology in Cracow in the years 1987-1993. Postepy Dermatol (Poznan) 1995; 12: 45-57.
46. Sohnle PG, Collins-Lech C. Analysis of the lymphocyte transformation response to Pityrosporum orbiculare in patients with tinea versicolor. Clin Exp Immunol 1982; 49: 559-564.
47. Adamski Z, Zaba R, Markowska A. Lymphoproliferative response of peripheral blood mononuclear cells in pityrosporum spp. infection. Postepy Dermatol (Poznan) 1993; 10: 61-66.
48. Sohnle PG, Collins-Lech C. Cell-mediated immunity to Pityrosporum orbiculare in tinea versicolor. J Clin Invest 1978; 62: 45-53.
49. Hashim FA, Elhassan AM. Tinea versicolor and visceral leishmaniasis. Int J Dermatol 1994; 33: 258-259.
50. Faergemann J. Antibodies to Pityrosporum orbiculare in patients with tinea versicolor and controls of various ages. J Invest Dermatol 1983; 80: 133-135.
51. Silva-Lizama E. Tinea versicolor. Int J Dermatol 1995; 34: 611-617.
52. De Luca C, Picardo M, Breathnach A, et al. Lipoperoxidase activity of Pityrosporum: characterization of by-products and possible role in pityriasis versicolor. Exper Dermatol 1996; 5: 49-56.
53. Nazzaro-Porro M. Identification of tyrosinase inhibitors in cultures of Pityrosporum. J Invest Dermatol 1978; 71: 205-208.
54. Soyer HP, Cerroni L. The significance of histopathology in the diagnosis of dermatomycoses. Acta Dermatovenerologica Alpina Pannonica et Adriatica (Ljubljana) 1992; 1: 84-87.
55. Galadari I, El-Komy M, Mousa A, et al. Tinea versicolor: histologic and ultrastructural investigation of pigmentary changes. Int J Dermatol 1992; 31: 253-256.
56. Tosti A, Villardita S, Fazzini ML. The parasitic colonization of the homey layer in tinea versicolor. J Invest Dermatol 1972; 59: 233-237.
57. Keddie FM. Electron microscopy of Malassezia furfur in tinea versicolor. Sabouraudia 1966; 5: 134-138.
58. Schwartz RA, Fox MD. Office Dermatology. Kansas City, Missouri: American Academy of Family Physicians Publications, 1991.
59. Baran E, Szepietowski J, Walów B, et al. Fungal skin infections in the Lower-Silesian region in the years 1974-1991. Part II. Localization of skin lesions. Przegl Dermatol 1993; 80: 49-58.
60. Terragni L, Lasagni A, Oriani A. Pityriasis versicolor of the face. Mycoses 1991; 34: 345-347.
61. Pontasch MJ, Kyanko ME, Brodell RT. Tinea versicolor of the face in black children in a temperate region. Cutis 1989; 43: 81-84.
62. Emiko Imazu L, Okamoto H, Imamura S. Pityriasis versicolor: a case report with lesions exclusively on lower limbs. Acta Dermatol Kyoto 1995; 90: 479-482.
63. Hay RJ, Roberts SOB, Mackenzie DWR. Mycology. In: Rook AR, Wilkinson DS, Ebling FJG, et al., eds. Textbook of Dermatology, 5th edn. Oxford: Blackwell Scientific Publications, 1991: 1176-1178.
64. Avram A, Rousselet G, Benazeraf C, Grupper Ch. "Pityriasis versicolor" de la verge. Bull Soc Fr Dermatol Syphiligr 1973; 80: 607-608.
65. Daneshvar SA, Hashimoto K. An unusual presentation of tinea versicolor in an immunosuppressed patient. J Am Acad Dermatol 1987; 17: 304-305.
66. Conill C, Azón-Masoliver A, Verger E, et al. Pityriasis versicolor confined to the radiation therapy field. Acta Oncol 1990; 29: 949-950.
67. Sykes N. Earwax and tinea versicolor. Int J Dermatol 1994; 33: 543-544.
68. Aly R, Berger T. Common superficial fungal infections in patients with AIDS. Clin Infect Dis 1996; 22: S128-S132.
69. Elmets CA. Management of common superficial fungal infections in patients with AIDS. J Am Acad Dermatol 1994; 31: S60-S63.
70. Faergemann J. Pityrosporum infections. J Am Acad Dermatol 1994; 31: S18-S20.
71. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for superficial mycotic infections of the skin: pityriasis (tinea) versicolor. Guidelines/Outcomes Committee. American Academy of Dermatology. J Am Acad Dermatol 1996; 34: 287-289.
72. Payle B, Serrano L, Bieley HC, Reyes BA. Albert's solution versus potassium hydroxide solution in the diagnosis of tinea versicolor. Int J Dermatol 1994; 33: 182-183.
73. Kovacs SO, Hruza LL. Superficial fungal infections. Getting rid of lesions that don't want to go away. Postgrad Med 1995; 98: 61-75.
74. Hacker SM. Common disorders of pigmentation: when are more than cosmetic cover-ups required? Postgrad Med 1996; 99: 177-186.
75. Elewski BE. Cutaneous mycoses in children. Br J Dermatol 1996; 134(Suppl. 46): 7-11.
76. Jacobs P. Treatment of fungal skin infections: state of the art. J Am Acad Dermatol 1990; 23: 549-551.
77. Rausch LJ, Jacobs PH. Tinea versicolor: treatment and prophylaxis with monthly administration of ketoconazole. Cutis 1984; 34: 470-471.
78. Faergemann J, Fredriksson T. Propylene glycol in the treatment of tinea versicolor. Acta Derm Venereol (Stockh) 1980; 60: 92-93.
79. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part I. J Am Acad Dermatol 1994; 30: 677-698.
80. Wasik F, Baran E, Vlizanowska A, et al. Clinical efficacy of 1% Metronidazol cream and gel. Przegl Dermatol 1993; 80: 172-179.
81. Nowicki R, Schrooten P, Sadowska E. Nizoral shampoo in the treatment of pityriasis versicolor. In: Szarmach H, ed. Advances in Pathogenesis, Diagnoses and Treatment of Skin and Venereal Diseases. Proceedings of the 24th Congress of the Polish Dermatologic Society. Gdańsk: Drukarnia Archidiecezji Gdańskiej, 1993: 187-191.
82. Urbanowski S, Nierebinska E, Gwiezdzinski Z, et al. Nisoral shampoo vs. selsun shampoo in the treatment of tinea versicolor. In: Szarmach H, ed. Advances in Pathogenesis, Diagnoses and Treatment of Skin and Venereal Diseases. Proceedings of the 24th Congress of the Polish Dermatologic Society. Gdańsk: Drukarnia Archidiecezji Gdańskiej, 1993: 191-195.
83. Turek-Urasińska K, Nowak A. Topical econazol in the treatment of common dermatomycoses. Postepy Dermatol (Poznan) 1993; 10: 67-73.
84. Lever LR, Dykes PJ, Thomas R, et al. How orally administered terbinafine reaches the stratum corneum. J Dermatol Treat 1990 (Suppl. 2); 1: 23-25.
85. Vermeer BJ, Staats CCG. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor: a placebo-controlled study. Dermatology 1997; 194 (Suppl. 1): 22-24.
86. Aste N, Pau M, Pinna AL, et al. Clinical efficacy and tolerability of terbinafine in patients with pityriasis versicolor. Mycoses 1991; 34: 353-357.
87. Birnbaum JE. Pharmacology of the allylamines. J Am Acad Dermatol 1990; 23(Suppl.): 782-785.
88. Fernandez-Nava HD, Laya-Cuadra B, Tianco EAV. Comparison of single dose 400 mg versus 10-day 100 mg daily dose ketoconazole in the treatment of tinea versicolor. Int J Dermatol 1997; 36: 64-66.
89. Jones HE. Pityriasis versicolor with ketoconazole [Letter reply], J Am Acad Dermatol 1989; 20: 704-705.
90. Faergemann J, Laufen H. Levels of fluconazole in serum, stratum corneum, epidermis-dermis (without stratum corneum) and eccrine sweat. Clin Exp Dermatol 1993; 18: 102-106.
91. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-268.
92. Lewis JH, Zimmerman HJ, Benson GD, Ishak KG. Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 1984; 86: 503-513.
93. Brusko CS, Marten JT. Ketoconazole hepatotoxicity in a patient treated for environmental illness and systemic candidiasis. Drug Intell Clin Pharm Ann Pharmacother 1991; 25: 1321-1325.
94. Urbanowski S, Nierebinska E, Gwiezdzinski Z, et al. Current problems and trends in development of antifungal agents. In: Szarmach H, ed. Advances in Pathogenesis, Diagnoses and Treatment of Skin and Venereal Diseases. Proceedings of the 24th Congress of the Polish Dermatologic Society. Gdańsk: Drukarnia Archidiecezji Gdańskiej, 1993: 117-121.
95. Delescluse J. Itraconazole in tinea versicolor: a review. J Am Acad Dermatol 1990; 23: 551-554.
96. Elewski B, Hay RJ. International Summit on Cutaneous Antifungal Therapy, Boston, Massachusetts, Nov. 11-13, 1994. J Am Acad Dermatol 1995; 33: 816-822.
97. Grant SM, Clissold SP. Itraconazole, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-344.
98. Hickman JG. A double-blind, randomized, placebo-controlled evaluation of short-term treatment with oral itraconazole in patients with tinea versicolor. J Am Acad Dermatol 1996; 34: 785-787.
99. Faergemann J. Treatment of pityriasis versicolor with itraconazole: a double-blind placebo controlled study. Mycoses 1988; 31: 377-379.
100. Del Palacio Hernandez A, Delgado Vicente S, Menendez Romos F, Rodriguez-Noriega Belaustegui A. Randomized comparative clinical trial of itraconazole and selenium sulfide shampoo for the treatment of pityriasis versicolor. Rev Infect Dis 1987; 9(Suppl 1): 121-127.
101. Stevens DA. The new generation of antifungal drugs. Eur J Clin Microbiol Infect Dis 1988; 7: 732-735.
102. Graybill JR, Sharkey PK. Fungal infections and their management. Br J Clin Pract 1990; 71: 23-31.
103. Cauwenbergh G, Van Cutsem J. Role of animal and human pharmacology in antifungal drug design. Ann N Y Acad Sci 1988; 544: 264-269.
104. Gupta AK, Sauder DN, Shear NH. Antifungal agents: an overview. Part II. J Am Acad Dermatol 1994; 30: 911-933.
105. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-917.